Median Technologies' eyonis® LCS receives CE marking

Median Technologies announces that its eyonis® LCS software has obtained CE marking. Designed for lung cancer screening, this artificial intelligence-based medical device can now be marketed in the European Union.

This marking, issued by GMED, guarantees compliance with European standards. eyonis® LCS promises to improve screening programs with greater accuracy in early detection and diagnosis, crucial for increasing the chances of survival.

Following FDA approval in the United States in February 2026, this development allows Median to access a significant European market, addressing pressing clinical needs, including the reduction of false positives and negatives.